Please ensure Javascript is enabled for purposes of website accessibility
Senators Grill Pharmaceutical CEOs About High Drug Prices
gvw_ap_news
By Associated Press
Published 6 years ago on
February 26, 2019

Share

WASHINGTON — Senators grilled CEOs of seven major drug companies on Tuesday over high prescription drug prices that are a drain on Medicare and Medicaid and a burden to millions of Americans. The extraordinary public accounting was a sign that Congress and the White House are moving toward legislation this year to curb costs.

“Without a doubt, drug pricing is a complex issue. But I think we should all be asking: Should it be so complex? We cannot allow anyone to hide behind the current complexities to shield the true cost of a drug.” — Chairman Charles Grassley
As the Finance Committee hearing got underway, Chairman Charles Grassley, R-Iowa, pointedly reminded the executives that it is a crime to provide false testimony to Congress. Some of the companies initially had sought a private meeting to explain their pricing policies, but lawmakers refused and insisted the CEOs appear in public or risk subpoenas.
“Without a doubt, drug pricing is a complex issue,” Grassley said in his prepared opening statement. “But I think we should all be asking: Should it be so complex? We cannot allow anyone to hide behind the current complexities to shield the true cost of a drug.”
Ranking Democrat Ron Wyden of Oregon said in his prepared statement, “You pharma executives are here because the way you do business is unacceptable and unsustainable. Ten companies accounted for half of all profits in the health care sector last fall. Nine of those ten were drug manufacturers.”
In statements submitted to the committee, the CEOs said drug development is a risky and costly undertaking and that prices reflect investment in research and development.

Dems: Time for Medicare to Leverage Purchasing Power

“We recognize that the current state of drug pricing in the U.S. health care system is not sustainable and that patients are facing increasingly high out-of-pocket costs,” AstraZeneca CEO Pascal Soriot said in prepared remarks. “We believe that these issues must be addressed urgently, and we hope to be a constructive partner in finding solutions.”
Tuesday’s hearing marks the first time lawmakers have called the industry’s top executives to account for rising prices. Previous congressional hearings have focused on bad actors who briefly captured national attention, such as former pharma executive Martin Shkreli, who hiked the price of a decades-old infection treatment by more than 5,000 percent.
Besides AstraZeneca, which makes the cholesterol drug Crestor, other companies represented at the hearing were AbbVie, maker of Humira for rheumatoid arthritis and other immune-system conditions; Bristol-Myers Squibb, maker of the blood thinner Eliquis; Johnson & Johnson, maker of Xarelto to prevent blood clots; Merck, maker of Januvia to treat diabetes; Pfizer, maker of Lyrica for nerve pain; and Sanofi, a leading manufacturer of insulin, including the Lantus brand. The drugmakers have collected tens of billions of dollars from government programs in recent years.
Grassley said that he’s not interested in “scapegoating” and that Congress intends to respond to the drug price problem in a “measured and effective” way.
Democrats say it’s time for Medicare to leverage its purchasing power and directly negotiate prices with the industry, a step most Republicans oppose.

Drugmakers Point Finger at Other Industry Players

The pharmaceutical industry is one of the most powerful lobbies in Washington, but Tuesday’s hearing seemed to mark a change in direction. President Donald Trump’s recurring blasts at drugmakers appear to be closer to finding a pathway to legislation.

“For a patient taking a drug that has no competition, the list price is meaningful.” — Chairman Charles Grassley
Drugmakers pointed a finger at other industry players, including middlemen called pharmacy benefit managers, who bargain on behalf of insurers and employers. Rebates paid to middlemen help assure favorable treatment for a medication on an insurer’s list of covered drugs and help keep premiums lower.
But the rebates are not passed on to consumers who use the particular medication, and they can face high copays based on the drug’s list price, not the discounted one. Experts say rebates can also create an incentive to keep raising list prices.
While list prices are going up, some of the CEOs said the net prices their companies receive after discounts and rebates are stable or sometimes declining.
Grassley seemed skeptical of the drugmakers’ argument that high list prices are not really part of the problem.
“For a patient taking a drug that has no competition, the list price is meaningful,” he said.

Offering Solutions of Their Own

The companies offered solutions of their own, some of which echo proposals from the administration or by lawmakers. Among them:
— Allow patients to share in rebates when they buy their medication, a policy proposed by the Trump administration.
— Place a hard limit on cost-sharing and copays for Medicare beneficiaries in the popular Part D prescription program, a change supported by Wyden.
— Make greater use of value based contracts that tie payments for a medication to how well it delivers results.
— Promote the introduction of lower-cost generics and biosimilars, competition that brand manufacturers are often accused of impeding.
Drug costs are squeezing Americans in a number of ways: New medicines for cancer and other diseases often launch with prices exceeding $100,000 per year even as employers are shifting more pharmacy costs onto workers. Less expensive drugs for common ailments like diabetes and asthma often see price hikes of around 10 percent annually. Meanwhile some drugmakers have been buying up once-cheap medicines and hiking prices by 1,000 percent or more.
The U.S. system for pricing drugs is notoriously complex. An expert panel assembled by the National Academy of Medicine in 2017 concluded it is “extremely difficult, if not impossible, for outsiders to ‘follow the money.'”
Critics say this lack of transparency has created a perverse system in which drugmakers, pharmacy benefit managers and other health care providers all benefit from rising prices.
The drug industry’s concerns about government intervention are on the rise. Drugmakers’ top lobbying arm, the Pharmaceutical Research and Manufacturers of America, spent a record $27.9 million last year to sway federal decision makers, according to records tallied by the nonprofit Center for Responsive Politics. That surpassed the group’s previous biggest spending total of $27.1 million during the 2009 congressional battle over President Barack Obama’s health care law, the Affordable Care Act, sometimes called Obamacare.

DON'T MISS

Elon Musk Reclaims Top Spot on Forbes’ Billionaires List

DON'T MISS

California Just Blew Its First Deadline for Voter-Approved Healthcare Measure

DON'T MISS

Trump Administration Halts Dozens of Research Grants at Princeton University

DON'T MISS

Fresno County Sheriff’s Pilot Takes His Last Flight as He Retires After 31 Years of Service

DON'T MISS

A Palestinian From the West Bank Is First Detainee Under 18 to Die in Israeli Prison, Officials Say

DON'T MISS

How Safe Is It to Walk to School? Fresno County Wants to Find Out

DON'T MISS

Baseball Is Back! How to Listen to Your MLB Favorites and the Grizzlies

DON'T MISS

Trump Says He’s Settled on a Tariff Plan That Is Set to Take Effect Wednesday

DON'T MISS

Auto Sales Surged in Anticipation of Trump’s Tariffs

DON'T MISS

Raid Or Rumor? Reports Of Immigrations Sweeps Are Warping Life In CA’s Central Valley

UP NEXT

Lakers Hold Off Rockets With 6 3-Pointers Apiece From Dorian Finney-Smith, Gabe Vincent

UP NEXT

Athletics Bat Boy Stewart Thalblum Takes Down Drone in Left Field

UP NEXT

NFL Postpones Tush Push Decision but Passes Other Rule Changes, AP Source Says

UP NEXT

March Madness: It’s South Carolina vs. Texas and UCLA vs. UConn in Women’s Final Four

UP NEXT

Major Layoffs Begin at Health Agencies That Track Disease and Regulate Food

UP NEXT

U.S. Bank Executive Terry Dolan Dies in Plane Crash Near Minneapolis

UP NEXT

Top Vaccine Official Resigns From FDA, Criticizes RFK Jr. for Promoting Misinformation, Lies

UP NEXT

Utah Becomes the First State to Ban Fluoride in Public Drinking Water

UP NEXT

Wilmer Flores’ 3-Run Homer in the 9th Inning Propels Giants to Victory Over Reds

UP NEXT

Democrats’ Popularity Plummets, yet Midterm Prospects Remain Strong

Fresno County Sheriff’s Pilot Takes His Last Flight as He Retires After 31 Years of Service

11 hours ago

A Palestinian From the West Bank Is First Detainee Under 18 to Die in Israeli Prison, Officials Say

11 hours ago

How Safe Is It to Walk to School? Fresno County Wants to Find Out

11 hours ago

Baseball Is Back! How to Listen to Your MLB Favorites and the Grizzlies

12 hours ago

Trump Says He’s Settled on a Tariff Plan That Is Set to Take Effect Wednesday

12 hours ago

Auto Sales Surged in Anticipation of Trump’s Tariffs

13 hours ago

Raid Or Rumor? Reports Of Immigrations Sweeps Are Warping Life In CA’s Central Valley

13 hours ago

House Speaker Johnson Fails to Squash a Proxy Voting Effort From New Moms in Congress

13 hours ago

UN Agency Closes Its Remaining Gaza Bakeries as Food Supplies Dwindle Under Israeli Blockade

14 hours ago

Hooters Goes Bust and Files for Bankruptcy Protection

14 hours ago

Elon Musk Reclaims Top Spot on Forbes’ Billionaires List

Elon Musk has reclaimed his position as the world’s wealthiest individual, according to Forbes’ 39th annual World’s Billio...

8 hours ago

8 hours ago

Elon Musk Reclaims Top Spot on Forbes’ Billionaires List

10 hours ago

California Just Blew Its First Deadline for Voter-Approved Healthcare Measure

Nassau Hall at Princeton University is in Princeton, N.J., Oct. 8, 2024. (AP File)
10 hours ago

Trump Administration Halts Dozens of Research Grants at Princeton University

After 31 years of service, Fresno County Sheriff’s Deputy IV and Pilot Michael Sill is retiring, having logged over 10,000 flight hours.
11 hours ago

Fresno County Sheriff’s Pilot Takes His Last Flight as He Retires After 31 Years of Service

Khalid Ahmad holds a poster of his 17-year-old son, Waleed, who died in an Israeli prison, that reads in Arabic, "The hero prisoner Martyr, mercy and eternity for our righteous Martyrs," in the West Bank town of Silwad, northeast of Ramallah Wednesday, March 26, 2025. (AP/Nasser Nasser)
11 hours ago

A Palestinian From the West Bank Is First Detainee Under 18 to Die in Israeli Prison, Officials Say

11 hours ago

How Safe Is It to Walk to School? Fresno County Wants to Find Out

12 hours ago

Baseball Is Back! How to Listen to Your MLB Favorites and the Grizzlies

Vehicles at an Audi showroom in Miami, March 29, 2025. President Donald Trump has said that tariffs would encourage auto companies and their suppliers to move to the U.S. (Saul Martinez/The New York Times)
12 hours ago

Trump Says He’s Settled on a Tariff Plan That Is Set to Take Effect Wednesday

Help continue the work that gets you the news that matters most.

Search

Send this to a friend